Keros Therapeutics, Inc. (NASDAQ:KROS) Stock Has Average Target Price of $20.50 According to Brokerages

Key Points

• Analyst consensus is “Hold” among nine analysts, with four buy ratings, four hold ratings, and one sell rating. The average 12-month price target is $20.50, compared with KROS’s opening price of $11.28.
• Keros Therapeutics reported quarterly adjusted earnings of -$1.45 per share, missing the consensus estimate of -$1.34, while analysts expect a full-year loss of $5.27 per share.
• The company authorized a $5 million stock buyback, representing up to 2.3% of outstanding shares. Institutional investors own 71.56% of the stock, while insiders have sold shares worth about $55,000 over the past three months.

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) have earned an average recommendation of "Hold" from the nine analysts that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $20.50.

A number of research analysts have weighed in on KROS shares. HC Wainwright reaffirmed a "buy" rating and issued a $20.00 price objective on shares of Keros Therapeutics in a report on Tuesday, August 4th. Wall Street Zen lowered shares of Keros Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday, September 5th. Weiss Ratings reissued a "sell (d-)" rating on shares of Keros Therapeutics in a research note on Wednesday, August 12th. Wells Fargo & Company dropped their target price on Keros Therapeutics from $20.00 to $18.00 and set an "overweight" rating on the stock in a research report on Tuesday, August 4th. Finally, Leerink Partners cut their price target on Keros Therapeutics from $30.00 to $23.00 and set an "outperform" rating for the company in a research note on Tuesday, August 4th.

Insider Activity at Keros Therapeutics

In other Keros Therapeutics news, insider Lorena Raquel Lerner sold 3,568 shares of Keros Therapeutics stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $10.29, for a total transaction of $36,714.72. Following the sale, the insider owned 27,559 shares of the company's stock, valued at $283,582.11. The trade was a 11.46% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 5,343 shares of company stock worth $54,985 in the last three months. 12.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Keros Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. acquired a new stake in Keros Therapeutics during the 2nd quarter worth $29,898,000. Nantahala Capital Management LLC acquired a new position in Keros Therapeutics in the second quarter valued at $15,091,483. Dimensional Fund Advisors LP increased its stake in Keros Therapeutics by 453.9% in the first quarter. Dimensional Fund Advisors LP now owns 321,360 shares of the company's stock valued at $3,547,000 after purchasing an additional 263,347 shares during the period. ADAR1 Capital Management LLC purchased a new stake in shares of Keros Therapeutics in the second quarter valued at about $2,641,000. Finally, Man Group plc purchased a new stake in shares of Keros Therapeutics in the second quarter valued at about $1,664,000. Institutional investors and hedge funds own 71.56% of the company's stock.

Keros Therapeutics Price Performance

NASDAQ KROS opened at $11.28 on Tuesday. The company has a market cap of $223.68 million, a price-to-earnings ratio of -3.05 and a beta of 1.01. The stock's fifty day moving average price is $10.88 and its 200 day moving average price is $11.03. Keros Therapeutics has a 1 year low of $9.69 and a 1 year high of $22.55.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its quarterly earnings results on Monday, August 3rd. The company reported ($1.45) earnings per share for the quarter, missing the consensus estimate of ($1.34) by ($0.11). Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 21.40%. Research analysts expect that Keros Therapeutics will post -5.27 earnings per share for the current year.

Keros Therapeutics announced that its board has initiated a stock buyback program on Wednesday, September 9th that permits the company to repurchase $5.00 million in outstanding shares. This repurchase authorization permits the company to repurchase up to 2.3% of its stock through open market purchases. Stock repurchase programs are often an indication that the company's management believes its stock is undervalued.

About Keros Therapeutics

Keros Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing medicines that regulate signaling within the transforming growth factor beta (TGF-β) superfamily. The company's research is aimed at addressing diseases in which abnormal signaling affects blood-cell production, bone health, muscle function, or cardiovascular health.

Keros has developed investigational ligand-trap therapies designed to modify signaling by activin and related proteins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.